Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH10-05-0269
Issue:2010: 104/1 (July) pp. 1-190
Pages:39-44

Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases

Q. Lian (1, 2), Y. Chow (1, 2), M. A. Esteban (3), D. Pei (3), H.-F. Tse (1)

(1) Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, China; (2) Research Centre of Heart, Brain, Hormone, and Healthy Aging, University of Hong Kong, Hong Kong, Hong Kong, China; (3) Stem Cell and Cancer Biology Group, Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

Summary

Recent advances in stem cell biology have transformed the understanding of cell physiology and developmental biology such that it can now play a more prominent role in the clinical application of stem cell and regenerative medicine. Success in the generation of human induced pluripotent stem cells (iPS) as well as related emerging technology on the iPS platform provide great promise in the development of regenerative medicine. Human iPS cells show almost identical properties to human embryonic stem cells (ESC) in pluripotency, but avoid many of their limitations of use. In addition, investigations into reprogramming of somatic cells to pluripotent stem cells facilitate a deeper understanding of human stem cell biology. The iPS cell technology has offered a unique platform for studying the pathogenesis of human disease, pharmacological and toxicological testing, and cell-based therapy. Nevertheless, significant challenges remain to be overcome before the promise of human iPS cell technology can be realised.

Keywords

Human induced pluripotent stem cells, reprogramming, drug screening, in vitro disease models

DOI

http://dx.doi.org/10.1160/TH10-05-0269

Articles

You've 182 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...